润达医疗
(603108)
| 流通市值：119.82亿 | | | 总市值：119.82亿 |
| 流通股本：6.04亿 | | | 总股本：6.04亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,176,286,324.36 | 4,135,268,017.92 | 2,072,478,429.77 | 9,147,372,720.28 |
| 营业收入 | 6,176,286,324.36 | 4,135,268,017.92 | 2,072,478,429.77 | 9,147,372,720.28 |
| 二、营业总成本 | 5,921,641,266.47 | 3,899,503,794.9 | 1,947,948,529.99 | 8,651,993,462.15 |
| 营业成本 | 4,592,846,859.28 | 3,014,617,835.12 | 1,517,089,491.53 | 6,715,744,820.25 |
| 税金及附加 | 31,418,567.63 | 22,664,129.15 | 11,491,620.14 | 47,071,452.31 |
| 销售费用 | 651,353,240.05 | 435,947,854.03 | 204,602,291.24 | 916,574,496.87 |
| 管理费用 | 328,121,993.25 | 210,983,836.94 | 105,053,330.6 | 508,780,760.73 |
| 研发费用 | 81,276,813.53 | 56,527,225.98 | 29,059,209.46 | 147,139,845.42 |
| 财务费用 | 236,623,792.73 | 158,762,913.68 | 80,652,587.02 | 316,682,086.57 |
| 其中:利息费用 | 237,011,916 | 160,870,448.74 | 81,137,488.54 | 334,043,326.1 |
| 其中:利息收入 | 10,713,409.58 | 8,270,129.61 | 3,056,394.8 | 22,940,044.19 |
| 加:投资收益 | 97,818,515.41 | 70,425,376.62 | 26,177,505.04 | 231,999,165.67 |
| 资产处置收益 | 5,542,547.12 | 2,958,813.52 | -284,992.29 | 11,774,743.77 |
| 资产减值损失(新) | -3,691,816.63 | -130,657.5 | -126,451.2 | -34,499,655.61 |
| 信用减值损失(新) | -112,898,735.77 | -86,987,136.6 | -72,525,156.7 | -88,900,920.89 |
| 其他收益 | 17,031,776.28 | 10,187,777.08 | 5,825,014.08 | 31,050,783.49 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 258,447,344.3 | 232,218,396.14 | 83,595,818.71 | 646,803,374.56 |
| 加:营业外收入 | 8,537,310.41 | 7,427,130.34 | 1,688,232.81 | 17,063,853.59 |
| 减:营业外支出 | 5,999,558.01 | 2,823,176.02 | 710,811.35 | 8,312,115.94 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 260,985,096.7 | 236,822,350.46 | 84,573,240.17 | 655,555,112.21 |
| 减:所得税费用 | 118,882,570.14 | 84,546,059.93 | 37,051,253.01 | 212,919,501.46 |
| 六、净利润 | 142,102,526.56 | 152,276,290.53 | 47,521,987.16 | 442,635,610.75 |
| 持续经营净利润 | 142,102,526.56 | 152,276,290.53 | 47,521,987.16 | 442,635,610.75 |
| 归属于母公司股东的净利润 | 50,424,910.92 | 91,306,078.58 | 22,603,808.03 | 273,296,495.22 |
| 少数股东损益 | 91,677,615.64 | 60,970,211.95 | 24,918,179.13 | 169,339,115.53 |
| (一)基本每股收益 | 0.08 | 0.15 | 0.04 | 0.47 |
| (二)稀释每股收益 | 0.08 | 0.15 | 0.04 | 0.47 |
| 八、其他综合收益 | 2,111,576.37 | 1,540,851.18 | 1,025,645.62 | -4,516,751.45 |
| 归属于母公司股东的其他综合收益 | 1,897,427.7 | 1,378,999.78 | 915,901.73 | -4,231,460.57 |
| 九、综合收益总额 | 144,214,102.93 | 153,817,141.71 | 48,547,632.78 | 438,118,859.3 |
| 归属于母公司股东的综合收益总额 | 52,322,338.62 | 92,685,078.36 | 23,519,709.76 | 269,065,034.65 |
| 归属于少数股东的综合收益总额 | 91,891,764.31 | 61,132,063.35 | 25,027,923.02 | 169,053,824.65 |
| 公告日期 | 2024-10-30 | 2024-08-29 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |